Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy

Oncology Letters

Volumn 2, Issue 2, 2011, Pages 303-308

  Hayashi, Mitsuhiro ^a,b   Kai, Kazuharu ^c   Okumura, Yasuhiro ^a   Osako, Tomofumi ^a   Arima, Nobuyuki ^a   Iwase, Hirotaka ^b   Nishimura, Reiki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Estrogen receptor; Neoadjuvant therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; SENSITIZATION;

EID: 79551621406     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.232     Document Type: Article

References (21)

1. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
3. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274, 2005.
4. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
5. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant tras- tuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377-384, 2010.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
7. Liu S, Dontu G and Wicha MS: Mammary stem cells, self- renewal pathways, and carcinogenesis. Breast Cancer Res 7: 86-95, 2005.
8. Kai K, Nishimura R, Arima N, Miyayama H and Iwase H: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin oncol 11: 426-433, 2006.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
10. Kurosumi M, Akashi-Tanaka S, Akiyama F, et al: Histo- pathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer 15: 5-7, 2008.
11. Kuroi K, Toi M, Tsuda H, Kurosumi M and Akiyama F: Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13: 38-48, 2006.
12. Toi M, Nakamura S, Kuroi K, et al: Phase II study of preop- erative sequential FEC and docetaxel predicts of pathological response and disease-free survival. Breast Cancer Res Treat 110: 531-539, 2008.
13. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749, 2001.
14. Gennari R, Menard S, Fagnoni F, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655, 2004.
15. Nahta R and Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215, 2006.
16. Ginestier C, Hur MH, Charafe-Jauffret E, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567, 2007.
17. Morimoto K, Kim SJ, Tanei T, et al: Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100: 1062-1068, 2009.
18. Li X, Lewis MT, Huang J, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.
19. Paluch-Shimon S, Wolf I, Goldberg H, et al: High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer. Acta Oncol 47: 1564-1569, 2008.
20. Chumsri S, Jeter S, Jacobs LK, et al: Pathologic complete response to preoperative sequential doxorubicin/cyclophos- phamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer 10: 40-45, 2010.
21. Chen XS, Wu JY, Huang O, et al: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep 23: 1213-1220, 2010.